Insider Buying: Tempest Therapeutics, Inc. (NASDAQ:TPST) Insider Buys $16,200.00 in Stock

Tempest Therapeutics, Inc. (NASDAQ:TPST) insider Justin Trojanowski acquired 7,500 shares of the company’s stock in a transaction on Friday, June 28th. The shares were purchased at an average cost of $2.16 per share, with a total value of $16,200.00. Following the completion of the purchase, the insider now directly owns 22,168 shares of the company’s stock, valued at $47,882.88. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Tempest Therapeutics Stock Down 0.5 %

Shares of TPST opened at $2.11 on Friday. Tempest Therapeutics, Inc. has a 12-month low of $0.17 and a 12-month high of $9.77. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.13 and a quick ratio of 3.13. The firm has a fifty day moving average price of $3.03 and a 200-day moving average price of $3.60.

Tempest Therapeutics (NASDAQ:TPST) last issued its earnings results on Thursday, May 9th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.08. On average, equities analysts expect that Tempest Therapeutics, Inc. will post -1.57 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have commented on TPST shares. HC Wainwright reaffirmed a “buy” rating and set a $47.00 price objective on shares of Tempest Therapeutics in a research note on Thursday, June 20th. Scotiabank started coverage on shares of Tempest Therapeutics in a research note on Thursday, March 14th. They set a “sector outperform” rating and a $13.00 price objective for the company. William Blair reaffirmed an “outperform” rating on shares of Tempest Therapeutics in a research note on Wednesday, March 20th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $8.00 price objective on shares of Tempest Therapeutics in a research note on Friday, June 21st. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $20.75.

Institutional Trading of Tempest Therapeutics

An institutional investor recently raised its position in Tempest Therapeutics stock. Virtu Financial LLC boosted its position in Tempest Therapeutics, Inc. (NASDAQ:TPST) by 69.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 28,574 shares of the company’s stock after purchasing an additional 11,689 shares during the quarter. Virtu Financial LLC owned approximately 0.13% of Tempest Therapeutics worth $112,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 22.52% of the company’s stock.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.